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Abstract Urothelial cell carcinoma (UCC) with musculus
detrusor (MD) invasion is treated by cystectomy. Subse-
quent pathologic evaluation of cystectomies does not reveal
MD invasion (<pT2) in a subgroup of patients. Our objec-
tive was to identify features at diagnostic transurethral re-
section (TUR) predicting down-staging (<pT2) at
cystectomy. Patients with pathologically confirmed MD in-
vasion at TUR followed by cystectomy for UCC without
(neo-) adjuvant therapy were included (N0106). Slides of
both TUR and cystectomy specimens were reviewed, and
survival analyses were performed. In total, 27/106 (26 %)
tumors were down-staged at cystectomy, of which 13 (12 %)
had no residual tumor (pT0). There was no significant
difference in age, gender, time interval between TUR and
operation, number of slides sampled, and presence of TUR
scar between down-staged (<pT2) and pT2 UCC. At review
of TUR specimens (N052) with UCC initially diagnosed as
pT2, MD invasion was not confirmed in eight cases (15 %).
One case showed extensive histiocytic reaction misinter-
preted as UCC; in four cases, muscularis mucosae had been
considered MD, and in three cases, desmoplastic reaction
mimicked MD. No histologic parameter at TUR was signif-
icantly associated with down-staging at cystectomy. Overall
and disease-specific survival was not statistically different in
down-staged and pT2 UCC. In conclusion, down-staging of
UCC (<pT2) at cystectomy occurred in 26 %. At review of
diagnostic TURs, MD invasion was not confirmed in 15 %.
No clinical or pathologic parameter was predictive for
down-staging at cystectomy. There was no difference in
survival between down-staged and pT2-staged UCC.
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Introduction
Bladder cancer is the fourth most common cancer in males
and ninth most common cancer in females [1]. The majority
of bladder tumors primarily appear as non-muscle invasive
disease (<pT2), whereas 20 % of urothelial carcinomas
(UCCs) are infiltrating the musculus detrusor (MD) at pre-
sentation. Up to 25 % of initially non-muscle invasive
tumors will eventually progress to MD invasive disease.
Tumors limited to the mucosa (pTa/pT1) are conservatively
treated, while bladder cancer infiltrating within or beyond
the MD (≥pT2) requires aggressive treatment [2, 3]. After
radical surgery, the 5-year recurrence free-survival of ≥pT2
UCC is only 56–58 % [4, 5]. Accurate pathologic staging of
UCC at diagnostic transurethral resection (TUR) specimens
is, therefore, an important parameter to determine the opti-
mal therapy for individual patients.
Although accurate pathological staging at diagnostic
TUR is pivotal for therapeutic decision-making, definite
tumor stage can only be perceived after pathologic evalua-
tion of cystectomy specimens. In a substantial number of
patients, no invasion in the MD is identified at cystectomy,
prompted by MD invasion at diagnostic TUR. These
patients either show residual UCC without stromal invasion
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(pTa), UCC with invasion of the lamina propria (pT1),
carcinoma in situ (CIS) (pTis), or no residual tumor at all
(pT0). Down-staging of UCC to pT0 in cystectomy speci-
mens is reported in 5 to 20 % [6–10]. Although down-
staging is a well-known feature, it can be confronting for
patient, urologist, and pathologist, raising the question
whether the initial diagnosis prompting radical surgery was
adequate.
Several pathologic features might mimic MD invasion of
UCC. Infiltration of the muscularis mucosae (MM) and
extensive desmoplastic stromal reaction can both be misin-
terpreted as MD invasion. Furthermore, it is not well-
established whether UCC located directly adjacent to but
not within the MD should be staged as pT2 disease. The
objective of the present study was (a) to identify clinical and
pathological features of UCC at diagnostic TUR, which
correspond with down-staging at cystectomy and (b) to
investigate the clinical outcome of patients with down-
staged UCC after cystectomy.
Material and methods
Study population
In this study, we included patients with pathologically con-
firmed MD invasion at diagnostic TUR, followed by cys-
tectomy for UCC without neo-adjuvant chemotherapy or
radiotherapy. All patients were treated for UCC of the uri-
nary bladder at Erasmus MC, location Dijkzigt, between
June 1989 and May 2010. Patients were routinely followed
up every 3 months on the first 2 years after cystectomy,
semiannually on the third to fifth year, and subsequently at
12-month intervals. In case of progression, patients were
followed up every 3 months. Loco-regional recurrent dis-
ease or distant metastases were assessed by CT of the
abdomen and pelvis, chest X-rays, and bone scans (if indi-
cated). Death was reported by treating physicians or general
practitioner. Follow-up was defined as time from operation
to event or last patient contact. Patients that deceased from
other causes than bladder cancer, or that were lost to follow-
up, were censored at the date of last contact. All clinical data
were collected retrospectively from the electronic patient
database.
Pathologic review
Slides of cystectomies and diagnostic TUR specimens were
retrieved from the archives and reviewed by a urogenital
pathologist (GvL). Initial diagnoses had been made by a
group of general clinical pathologists. At review, stage and
grade were reassigned according the UICC 2002 TNM
staging system and the WHO grading system 1973 and
2004, respectively. The following additional pathological
parameters were recorded at review of the cystectomy
specimens: number of slides of the urinary bladder
sampled, presence of a TUR scar, and presence of
CIS. At review of the diagnostic TUR specimens, the
depth of invasion was established paying special atten-
tion to potential pitfalls such as MM invasion, extensive
desmoplastic stromal reaction, invasion adjacent to but
not within the MD, and invasion in between MD bun-
dles. If classification was uncertain based on routine
haematoxylin and eosin staining (HE), immunohisto-
chemistry was performed. In case MD invasion was
not obvious despite histology and additional immuno-
histochemistry, the tumor was classified as pT1 (N01),
which is similar to our approach in daily practice, in
which these tumors are reported as “pT1 at least.” The
use of the samples for research purposes was approved
by the Erasmus MC Medical Ethics Committee accord-
ing to the Medical Research Involving Human Subjects
Act (MEC-2004-261).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections
(5 μm) from TUR specimens were cut and mounted
on aminoacetylsilane-coated slides (Starfrost, Berlin,
Germany). Sections were deparaffinised in EZprep
(Roche Diagnostics, Indianapolis, IN, USA). For all
antibodies, heat-induced epitope retrieval was performed
in CC1 buffer (high pH) (Roche Diagnostics) for
64 min. The slides were incubated with monoclonal
Desmin antibody (clone DE-R-11; 1:50; Novocastra,
Newcastle, UK) or monoclonal keratin 7 antibody
(clone OV-TL 12/30; 1:1,000; Biogenex, San Ramon,
CA, USA) at 36 °C for 32 min, followed by amplifica-
tion using UltraView Universal DAB detection kit
(Roche Diagnostics). All reactions were performed in
an automatic BenchMark Ultra device (Roche Diagnos-
tics). Finally, the slides were counterstained, dehydrated,
cleared in xylene, and mounted in Pertex (Histolab
Products, Gothenburg, Sweden).
Statistical analysis
For comparison of continuous and categorical parameters of
the pT2 and the down-staged group at cystectomy, Mann–
Whitney and Fisher's exact test were performed, respective-
ly. Kaplan–Meier curves with log-rank analysis were used
for comparison of survival. A p value <0.05 was considered
statistically significant. All analyses were performed using
the Predictive Analytics Software 17 (SPSS Inc., Chicago,
IL, USA).
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Results
Patient characteristics
Between May 1989 and June 2010, a total of 160
patients had undergone cystectomy for a urothelial ma-
lignancy at Erasmus MC, comprising of 135 (84.4 %)
males and 25 (15.6 %) females (Table 1). The mean age
of the patients at operation was 62.4 years (range 33.2–
82.5 years). The majority of male patients had undergone
a radical cystoprostatectomy (N0128; 94.8 %), which
was combined by a left (N04), right (N04), or bilateral
(N01) nephro-ureterectomy. Four (3.0 %) male patients
had been treated by simple cystectomy, of whom three
had undergone a previous radical prostatectomy for pros-
tate adenocarcinoma. Three men (2.2 %) had been treated
by partial cystectomy. A total of 17 (68 %) female
patients had undergone a cysto-hysterectomy with adnexa
extirpation, combined with a left (N01) or right (N01)
nephro-ureterectomy. Eight (32 %) females had been
treated with simple cystectomy (Table 1).
The clinical indication for cystectomy was UCC with
MD invasion (≥cT2) in 137 patients (85.7 %), therapy-
resistant recurrence of superficial high grade pTa/pT1
UCC and/or CIS (N017; 10.6 %), involvement of the pros-
tatic urethra by superficial high grade UCC/CIS (N04;
2.5 %), a very large superficial UCC (pTa; N01; 0.6 %),
and urothelial CIS combined with sigmoid adenocarcinoma
with potential involvement of the urinary bladder (N01;
0.6 %). Of the 137 patients who had been operated for
MD invasion, 23 (16.8 %) patients had undergone neo-
adjuvant therapy and 8 (5.8 %) had clinical MD invasion
without pathological confirmation. For further analysis, we
included the remaining 106 (77.4 %) patients who had
pathologically confirmed MD invasion (≥pT2) at diagnostic
TUR, followed by cystectomy without neo-adjuvant
therapy.
Characterization of down-staged UCC
Of the 106 patients with ≥pT2 UCC at TUR, histologic
evaluation of the cystectomy specimen revealed 13 cases
(12.3 %) without residual tumor (pT0), 5 (4.7 %) with CIS
only, 3 (2.8 %) with pTa, 6 (5.7 %) with pT1, 33 (31.1 %)
with pT2, 37 (34.9 %) with pT3, and 9 (8.5 %) with pT4
disease. Therefore, 27 (25.5 %) cases had lower stage UCC
at cystectomy, then at initial diagnostic TUR, which showed
≥pT2 disease (Table 2). No statistically significant differ-
ence in age (p00.64), gender (p01.00), or number of days
between diagnostic TUR and operation (p00.96) existed
Table 2 Tumor charac-
teristics of 106 patients
with ≥pT2 on diagnostic
transurethral resection
(TUR), followed by
cystectomy for urothe-
lial cell carcinoma
without (neo-) adjuvant
therapy
CIS carcinoma in situ,
PUNLMP papillary uro-
thelial neoplasm of low
malignant potential, LG
low grade, HG high
grade
N0106 No. of patients (%)
Stage
pT0 13 (12)
pTis 5 (5)
pTa 3 (3)
pT1 6 (6)
pT2 33 (31)
>pT2 46 (43)
Concomitant
CIS
16
Grade
WHO 1973
No tumor 13 (12)
G1 0 (0)
G2 9 (9)
G3 79 (79)
WHO 2004
No tumor 13 (12)
PUNLMP 0 (0)
LG 0 (0)
HG 88 (88)
Table 1 Clinical characteristics of 160 patients operated for urothelial
cell carcinoma
N0160 No. of patients (%)
Age (median; range) 62.4 (33.2–82.5)
Sex
Male 135 (84)
Female 25 (16)
Type of operation
Male
Radical cystoprostatectomy 128 (95)
With nephro-ureterectomy 9
Simple cystectomy 4 (3)
Partical cystectomy 3 (2)
Female
Cysto-hysterectomy with adnexa
extirpation
17 (68)
With nephro-ureterectomy 2
Simple cystectomy 8 (32)
Indication for cystectomy
Musculus detrusor invasion 137 (86)
Therapy-resistant recurrent pTa/pT1 or CIS 17 (11)
Involvement of the prostatic urethra
by UCC/CIS
4 (2)
Very large superficial high grade UCC 1 (0.5)
Urothelial CIS combined with sigmoid
adenocarcinoma
1 (0.5)
UCC urothelial cell carcinoma, HG high grade, CIS carcinoma in situ
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between down-staged (<pT2) and concordantly staged
(≥pT2) cystectomies (Table 3).
To investigate whether down-staging was due to differ-
ence in sampling, we histologically reviewed all cystectomy
slides of ≤pT2 UCC. Stages pT3 and pT4 were not evalu-
ated (N046). In two cases, slides were not available for
review, leaving a total of 58 cases for analysis. The mean
number of slides sampled from the urinary bladder was ten
in both the down-staged and the concordantly staged pT2
group (p00.62). Histological reaction to previous TUR was
found in 20/27 (74 %) cases of the down-staged group as
compared to 17/31 (55 %) cases in the pT2 group (p00.13),
indicating that under-sampling of the cystectomy specimen
was not the cause of tumor down-staging after operation
(Table 3).
In order to find histological features at diagnostic TUR
that corresponded with down-staging at cystectomy, we
reviewed all diagnostic TUR slides of the 58 patients with
≤pT2 UCC. Six cases were not available for review, leaving
52 cases for further analysis. At review, one case showed
extensive histiocytic infiltration while no UCC was found in
the diagnostic TUR specimen, which was verified with
Fig. 1 Assessment of urothelial cell carcinoma invasion in relation to the
musculus detrusor. a, b Urothelial carcinoma invading in between mus-
culus detrusor fascicles. c Urothelial cancer located adjacent to but no in
between musculus detrusor fascicles. dHistiocytic reaction after previous
diagnostic transurethral resection, misinterpreted as urothelial cancer
invading the musculus detrusor. HE; original magnifications ×100
Table 3 Clinical (N0106) and pathologic (N058) characteristics of down-staged (<pT2) and ≥pT2 urothelial carcinoma at cystectomy
No. Clinico-pathologic variable Down-staged <pT2 ≥pT2 p value
106 Age (median; range) 64.9 (35.1–73.9) 64.1 (33.2–82.5) 0.64
Male/female (%) 23:4 (85/15) 68:11 (86/14) 1.00
Time after TUR (days) (median; range) 57 (15–113) 55 (12–220) 0.96
58 Number slides (median; range) 10 (3–33) 10 (2–23) 0.62
TUR reaction (%) 20/27 (74) 17/31 (55) 0.13
Review of pathologic cystectomy characteristics was performed only on the down-staged (<pT2) and pT2 urothelial cancers
TUR transurethral resection
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Fig. 3 Survival analysis of down-staged and pT2-staged urothelial cell carcinoma after cystectomy. There was no difference in overall a (p00.53)
or disease-specific b (p00.76) survival of patients with <pT2 versus pT2 urothelial cancer at cystectomy
Fig. 2 Pitfalls of urothelial cell carcinoma invasion of musculus detrusor. a, b Muscularis mucosae fascicles mimicking musculus detrusor. c, d
Extensive desmoplastic stromal reaction misinterpreted as musculus detrusor invasion. HE; original magnifications ×100
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negative immunohistochemical Ker7 staining (Fig. 1).
This case was incorrectly diagnosed as UCC at the time
of diagnosis; subsequent cystoprostatectomy indeed did
not reveal UCC (pT0). In the remaining 51 cases, grade
according to WHO 1973 (p00.28) or 2004 (p00.26),
and concomitant CIS (p00.55) were not associated with
down-staging at cystectomy. Of the tumors, 40/51
(78.4 %) demonstrated invasion into the MD, 4
(7.8 %) showed tumor adjacent to the MD but not in
between the muscle fascicles, and 7 (13.5 %) did not
reveal invasion up to MD bundles convincingly (Fig. 2).
Of these seven cases, four (7.7 %) showed invasion in
between small smooth muscle fascicles, which were not
characteristic for MD, but could represent MM and
three (5.8 %) demonstrated extensive desmoplastic stro-
mal reaction without tumor infiltration into the MD. The
desmoplastic stromal reaction was probably interpreted
as MD invasion at initial diagnosis (Fig. 3). In four
cases, Desmin immunohistochemistry expression was
used to facilitate identification of smooth muscle fas-
cicles at review, in case of cauterization or differentia-
tion with desmoplastic stromal reaction. There was no
significant relation of the type of tumor invasion in the
TUR specimen and the subsequent findings at cystec-
tomy (Table 4).
Survival analysis
The mean follow-up of the pT2 group and the down-
staged group was 61.6 and 70.9 months, respectively.
To investigate whether patients who were down-staged
at cystectomy had a favorable outcome versus those
with stage pT2 at cystectomy, survival analysis was
performed. We excluded 9/60 (15 %) patients with
positive regional lymph nodes from the analysis, i.e.,
4/27 (14.8 %) in the down-staged group and 5/33
(15.2 %) in the pT2 group. There was no significant
difference in overall (p00.53) and disease-specific (p0
0.76) survival between the adequately staged and down-
staged group (Fig. 3).
Discussion
In a significant number of cases, urologists and pathologists
are confronted with UCC down-staged (<pT2) at cystec-
tomy, although operation was prompted by an MD invasive
tumor at diagnostic TUR. Down-staging at cystectomy
might have several causes, such as successful neo-adjuvant
therapy, complete UCC resection at TUR, or false-positive
diagnosis at TUR. In the present study, we investigated the
incidence and the possible origin of down-staging in a well-
defined cohort of 106 cystectomy patients, of whom opera-
tion was prompted by pathologic MD invasion at diagnostic
TUR and who had not undergone neo-adjuvant therapy.
We found down-staging at cystectomy in 26 % of the study
population. In 12 %, no residual UCC (pT0) was identified,
which is in line with numbers (6–20 %) reported by others
[6–9]. Age, gender, and interval between TUR and operation
were not statistically different between concordantly staged
pT2 and the down-staged group. Since the number of slides
sampled at grossing and frequency of identifying a TUR scar at
microscopic evaluation of cystectomy specimens was similar
in both groups, down-staging was not due to sampling error.
At review of the diagnostic TUR specimens, in 12 out of
52 (23.1 %) cases, UCC infiltration into the MD could not
be confirmed. Discrepancy with the original TUR staging
was caused by false interpretation of (a) histiocytic reaction
as invasive UCC (1.9 %), (b) invasion of the MM as MD
invasion (7.7 %), (c) extensive desmoplastic stromal reac-
tion as MD (5.8 %), and (d) UCC impinging upon the MD
as invasion into the MD (7.7 %). As far as we know, the
latter subtle distinction has not been subject of study yet. If
UCC adjacent to MD would be classified as pT2 disease, as
is often done in pathologic practice, the prevalence of down-
staging UCC at review of TUR specimens was 15.4 % (8/52).
Interestingly, this percentage of staging discordance is in line
with the percentage of original pT1 UCC up-staged to pT2
disease at review, indicating that inter-observer variability is
also existing in assessing MD invasion [11]. Distinguishing
between MM and MD invasion at diagnostic TUR is a well-
known challenge in surgical pathology, which is hampered
Table 4 Pathologic characteris-
tics of urothelial cell carcinoma
at diagnostic transurethral resec-
tions (TUR) in the down-staged
(N021) and adequately pT2-
staged group (N030)
LG low grade, HG high grade,
CIS carcinoma in situ, MM
muscularis mucosae, MD mus-
culus detrusor
N051 Down-staged Adequate pT2 p value
N (%) N (%)
G2/G3 2/19 (10/90) 7/23 (23/77) 0.28
LG/HG 0/21 (0/100) 3/27 (10/90) 0.26
Concomitant CIS 8 (38) 9 (30) 0.55
Desmoplastic stromal reaction 0 (0) 3 (100) N/A
MM invasion 2 (50) 2 (50) 1.00
Adjacent to MD 2 (50) 2 (50) 1.00
In between MD fascicles 17 (43) 23 (57) 1.00
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by problems in tissue orientation and potential MM
hyperplasia. In addition, MD-infiltrating tumors may
partially destruct muscle fibers, leaving thin residual
MD bundles resembling MM [12]. Despite these diffi-
culties, accurate recognition of MD invasion is crucial
for patient treatment according to the current guidelines.
Immunohistochemical expression of the cytoskeletal pro-
tein Smoothelin is reported to be stronger in MD than
in MM [13–15]. Therefore, additional immunohisto-
chemistry using Smoothelin can be useful in differenti-
ating both muscle layers. While variable Smoothelin
expression patterns can be appreciated when both layers
are present in the same specimen, its value in classify-
ing a limited amount of smooth muscle fibers in small
specimens remains to be established. Therefore, we de-
cided not to include this marker in the current study.
Finally, extensive desmoplastic myofibroblastic reaction
evoked by UCC invasion might histologically mimic
MD [16]. In this case, immunohistochemical detection
of Desmin is helpful to distinguish myofibroblasts from
MD smooth muscle cells [17].
No statistically significant difference in overall and
disease-specific survival was found between the down-
staged and concordantly staged pT2 group. Interestingly,
the percentage of patients with positive lymph nodes was
similar between the two groups as well. Regarding the
patients with pT0 disease, survival after cystectomy was
not different from the patients with higher tumor stages.
This is in accordance with the findings of Thrasher et al.
[18]. This implicates that MD invasive UCC at diagnostic
TUR with down-staging at cystectomy should still be
regarded as pT2 disease. The clinical significance of pT0
disease at cystectomy is, however, still under debate.
Volkmer et al. excluded patients with neo-adjuvant therapy
and found a significantly better disease-specific survival in
patients with pT0 disease at cystectomy versus patients with
maximal pT2a disease at cystectomy [19]. Likewise, Tilki et
al. investigated a group of 4,430 patients treated with radical
cystectomy and found significantly better clinical outcomes
in patients with pT0 disease than those with clinical and
pathological stage T2 [20]. These results are conflicting
with the findings in our study, which could be explained
by the fact that in our study a relatively small number of
patients were included.
This relatively low number of patients is a limitation of
this study and was due to our strict selection criteria, i.e.,
exclusion of non-urothelial cancer such as squamous carci-
noma and adenocarcinoma, presence of neo-adjuvant thera-
py, availability of slides for review, and omitting high-stage
disease (pT3/4) from analysis. Nevertheless, to the best of
our knowledge, this is the first study specifically investigat-
ing the nature of down-staging in UCC, in which we retro-
spectively demonstrate 15 % inter-observer variability in the
diagnosis of clinically decisive MD invasion. For practical
purposes, important lessons can be drawn from this study.
First, UCC invasion directly adjacent to MD bundles can be
classified as pT2 disease at TUR since down-staging in this
group did not occur more frequently than in UCC with
invasion into the MD fascicles. Secondly, the presence of
pT2 disease at cystectomy in patients with MM invasion or
extensive desmoplastic stromal reaction yet no MD invasion
at TUR as well as the significant inter-observer variability of
T1-2 staging raises the question whether the current clinico-
pathologic guidelines for treatment of invasive UCC can be
optimized. Herr performed a re-staging TUR in patients
with histologically proven pT2 disease [21]. If re-staging
revealed pT0 or pT1 disease, patients were offered immediate
cystectomy or careful follow-up. Interestingly, the 10-year
disease-specific survival was similar in both groups with
significantly better survival in patients with pT0 as compared
to pT1 tumor at re-staging. Since cystectomy is a surgical
procedure with 90-day complication rates as high as 46 % and
peri-operative mortality ranging from 1 to 4 % [3, 22], further
studies on the use of re-TUR and imaging modalities for the
treatment and follow-up as alternative for radical operation in
a subgroup of UCC patients are mandatory.
In conclusion, we have shown that 26 % of patients with
initial pT2 stage at diagnostic TUR were down-staged at
subsequent cystectomy. No clinical or pathologic parame-
ters could be identified that were associated with down-
staging (<pT2) of UCC at cystectomy. Review of diagnostic
TUR specimens revealed inter-observer variability, with
pT2 to <pT2 in 15 % of the cases. No difference in survival
was found in patients with down-staged versus pT2 UCC at
cystectomy.
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